295 related articles for article (PubMed ID: 33146795)
1. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma.
Kim SS; Lee S; Kim MJ
Eur Radiol; 2021 May; 31(5):3405-3416. PubMed ID: 33146795
[TBL] [Abstract][Full Text] [Related]
2. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
[TBL] [Abstract][Full Text] [Related]
5. LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI.
Choi SH; Lee SS; Park SH; Kim KM; Yu E; Park Y; Shin YM; Lee MG
Radiology; 2019 Feb; 290(2):388-397. PubMed ID: 30422088
[TBL] [Abstract][Full Text] [Related]
6. Recurrence After Curative Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: Diagnostic Algorithms on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging.
Wang W; Yang C; Zhu K; Yang L; Ding Y; Luo R; Zhu S; Chen C; Sun W; Zeng M; Rao SX
Liver Transpl; 2020 Jun; 26(6):751-763. PubMed ID: 31901208
[TBL] [Abstract][Full Text] [Related]
7. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
[TBL] [Abstract][Full Text] [Related]
8. Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma?
Wei H; Jiang H; Liu X; Qin Y; Zheng T; Liu S; Zhang X; Song B
Eur J Radiol; 2020 Nov; 132():109312. PubMed ID: 33022551
[TBL] [Abstract][Full Text] [Related]
9. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
[TBL] [Abstract][Full Text] [Related]
10. Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
Heo S; Kang HJ; Choi SH; Kim S; Yoo Y; Choi WM; Kim SY; Lee SS
Eur Radiol; 2024 May; 34(5):2974-2985. PubMed ID: 37848775
[TBL] [Abstract][Full Text] [Related]
11. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
[TBL] [Abstract][Full Text] [Related]
12. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of LI-RADS category on gadoxetic acid-enhanced MRI and 18F-FDG PET-CT in patients with primary liver carcinomas.
Min JH; Kim SH; Hwang JA; Hyun SH; Ha SY; Choi SY; Kim SW; Kim HS
Eur Radiol; 2021 Jun; 31(6):3649-3660. PubMed ID: 33211142
[TBL] [Abstract][Full Text] [Related]
14. Subtraction Images From Portal Venous Phase Gadoxetic Acid-Enhanced MRI for Observing Washout and Enhancing Capsule Features in LI-RADS Version 2018.
Chung JW; Yu JS; Choi JM; Cho ES; Kim JH; Chung JJ
AJR Am J Roentgenol; 2020 Jan; 214(1):72-80. PubMed ID: 31573851
[No Abstract] [Full Text] [Related]
15. LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection.
Wei H; Jiang H; Zheng T; Zhang Z; Yang C; Ye Z; Duan T; Song B
Eur Radiol; 2021 Apr; 31(4):2289-2302. PubMed ID: 33001306
[TBL] [Abstract][Full Text] [Related]
16. Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery.
Kang HJ; Kim H; Lee DH; Hur BY; Hwang YJ; Suh KS; Han JK
Radiology; 2021 Sep; 300(3):572-582. PubMed ID: 34227881
[TBL] [Abstract][Full Text] [Related]
17. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI.
Jeon SK; Joo I; Bae JS; Park SJ; Lee JM
Eur Radiol; 2022 Jan; 32(1):46-55. PubMed ID: 34132875
[TBL] [Abstract][Full Text] [Related]
18. Simplified LI-RADS for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI.
Kwag M; Choi SH; Choi SJ; Byun JH; Won HJ; Shin YM
Radiology; 2022 Dec; 305(3):614-622. PubMed ID: 35972362
[TBL] [Abstract][Full Text] [Related]
19. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
[TBL] [Abstract][Full Text] [Related]
20. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid-enhanced liver MRI.
Kang HJ; Lee JM; Jeon SK; Jang S; Park S; Joo I; Yoon JH; Han JK
Eur Radiol; 2021 Feb; 31(2):824-833. PubMed ID: 32845387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]